# A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.

> **NCT00197067** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 200 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** RTS,S/AS02D and RTS,S/AS02A

## Key facts

- **NCT ID:** NCT00197067
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03-15
- **Primary completion:** 2005-04-26
- **Final completion:** 2005-04-26
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2019-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00197067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00197067, "A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00197067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*